WO2005070136A2 - Up-regulation of bone morphogenetic protein (bmp) gene expression in bone cells by electromagnetic signals - Google Patents

Up-regulation of bone morphogenetic protein (bmp) gene expression in bone cells by electromagnetic signals Download PDF

Info

Publication number
WO2005070136A2
WO2005070136A2 PCT/US2005/000793 US2005000793W WO2005070136A2 WO 2005070136 A2 WO2005070136 A2 WO 2005070136A2 US 2005000793 W US2005000793 W US 2005000793W WO 2005070136 A2 WO2005070136 A2 WO 2005070136A2
Authority
WO
WIPO (PCT)
Prior art keywords
bone
specific
signal
gene expression
bmp
Prior art date
Application number
PCT/US2005/000793
Other languages
French (fr)
Other versions
WO2005070136A3 (en
Inventor
Carl T. Brighton
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020067013999A priority Critical patent/KR101324824B1/en
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Priority to JP2006549515A priority patent/JP4801802B2/en
Priority to EP05705445A priority patent/EP1716228A4/en
Priority to US10/585,718 priority patent/US8017369B2/en
Priority to CA2553199A priority patent/CA2553199C/en
Priority to BRPI0506826-6A priority patent/BRPI0506826A/en
Priority to CN2005800047115A priority patent/CN1918285B/en
Priority to AU2005206794A priority patent/AU2005206794B2/en
Priority to NZ548447A priority patent/NZ548447A/en
Publication of WO2005070136A2 publication Critical patent/WO2005070136A2/en
Publication of WO2005070136A3 publication Critical patent/WO2005070136A3/en
Priority to IL176783A priority patent/IL176783A/en
Priority to NO20063444A priority patent/NO20063444L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/326Applying electric currents by contact electrodes alternating or intermittent currents for promoting growth of cells, e.g. bone cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/40Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/51Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor

Definitions

  • the present invention is directed to a method of up-regulating bone morphogenetic protein (BMP) gene expression in bone cells via the application of fields generated by specific and selective electric and electromagnetic signals for the treatment of injured or diseased bone, as well as devices for generating such signals.
  • BMP bone morphogenetic protein
  • Bone demineralizes and becomes abnormally rarefied.
  • Bone comprises an organic component of cells and matrix as well as an inorganic or mineral component.
  • the cells and matrix comprise a framework of collagenous fibers that is impregnated with the mineral component of calcium phosphate (85%) and calcium carbonate (10%) that imparts rigidity to the bone.
  • calcium phosphate 85%
  • calcium carbonate 85%
  • osteoporosis is generally thought as afflicting the elderly, certain types of osteoporosis may affect persons of all ages whose bones are not subject to functional stress. In such cases, patients may experience a significant loss of cortical and cancellous bone during prolonged periods of immobilization.
  • PEMF Pulsed electromagnetic fields
  • CC capacitive coupling
  • the present invention builds upon the technique described therein by describing the method of regulating expression of one targeted gene family, namely, bone morphogenetic protein(s) gene expression, through application of a field generated by a specific and selective electrical and electromagnetic signal, for the treatment of fresh fractures, fractures at risk, delayed unions, nonunion of fractures, bone defects, spine fusions, osteonecrosis or avascular necrosis, as an adjunct to other therapies in the treatment of one or all of the above, and in the treatment of osteoporosis.
  • one targeted gene family namely, bone morphogenetic protein(s) gene expression
  • a field generated by a specific and selective electrical and electromagnetic signal for the treatment of fresh fractures, fractures at risk, delayed unions, nonunion of fractures, bone defects, spine fusions, osteonecrosis or avascular necrosis
  • the present invention relates to regulating bone morphogenetic protein gene expression in bone cells via the application of fields generated by specific and selective electric and/or electromagnetic signals.
  • the optimal signal for up-regulating bone morphogenetic protein mRNA in bone cells was discovered.
  • the optimal signal generated a capacitively coupled electric field with an amplitude of 20 mV/cm, a duration of 24 hours, a frequency of 60 kHz, a duty cycle of 50%, and a sine wave configuration.
  • the present invention relates to up-regulating bone morphogenetic protein (BMP) gene expression in bone cells via the application of fields generated by such signals.
  • BMP bone morphogenetic protein
  • methods are provided to specifically and selectively up-regulate the gene expression (as measured by mRNA) of BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7, with capacitively coupled electric fields, electromagnetic fields, or combined fields.
  • a capacitively coupled electric field of about 20 mN/cm with an electric field duration of about 24 hours, a frequency of 60 kHz, a duty cycle of about 50%, and a sine wave configuration that causes the expression of BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7 rnR ⁇ As to be up-regulated.
  • a "specific and selective" signal is a signal that has predetermined characteristics of amplitude, duration, duty-cycle, frequency, and waveform that up-regulates the expression of the BMP genes (specificity).
  • the present invention relates to methods and devices for the treatment of fresh fractures, fractures at risk, delayed unions, nonunions, bone defects, spine fusion, osteonecrosis, as an adjunct to other therapies treating one or more of the above, and in the treatment of osteoporosis.
  • the method of the invention also includes the methodology for determining the "specific and selective" signal for BMP gene expression by methodically varying the duration of a starting signal known to increase, or suspected to increase, cellular production of BMPs. After finding the optimal duration, the amplitude of the signal is varied for the optimal duration of time as determined by the gene expression of BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7. The duty cycle, frequency, and waveform are varied methodically in the same dose response manner as above while keeping the other signal characteristics constant. This process is repeated until the optimal signal is determined that produces the greatest increase in the expression of BMPs.
  • Figure 1 is a graphic representation of the mRNA expression of BMP-2, BMP-4, BMP- 5, BMP-6, and BMP-7 when bone cells are exposed to a 20 mN/cm capacitively coupled electric field for various time durations. As indicated, the maximum expression for the various BMP mR ⁇ As occurred with a signal of 24 hours duration.
  • Figure 2 is a graphic representation of mRNA expression of BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7 when bone cells are exposed to various capacitively coupled electric field amplitudes with a duration of 24 hours. As indicated, the maximum expression for the various BMP mRNAs occurred with a field amplitude of 20 mN/cm.
  • Figure 3 is a graphic representation of mRNA expression of BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7 when bone cells are exposed to various capacitively coupled electric field frequencies with a field amplitude of 20 mV/cm and a signal duration of 24 hours. As indicated, the maximum expression for the various BMP mRNAs occurred with a frequency of 60 kHz.
  • Figure 4 is a graphic representation of mRNA expression of BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7 when bone cells are exposed to various capacitively coupled electric field duty cycles with a frequency of 60 kHz, a field amplitude of 20 mN/cm, and a signal duration of 24 hours. As indicated, the maximum expression for the various BMP rnR ⁇ As occurred with a 50% duty cycle.
  • FIG. 5 is a graphic representation of mR A expression of BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7 when bone cells are exposed to a capacitively coupled electric field of a 50% duty cycle of various on-off times with a field amplitude of 20 mN/cm and a frequency of 60 kHz. As indicated, the maximum expression for the various BMP mR ⁇ As occurred with a 1 minute ON / 1 minute OFF 50% duty cycle.
  • FIG. 6 is a graphic representation of BMP-2 mRNA expression when bone cells are exposed to a capacitively coupled continuous 50% duty cycle signal (20 mV/cm, 60 kHz, sine wave) versus a pulsed 50% duty cycle signal. As indicated, both signals showed essentially the same five- fold increase in BMP-2 mRNA.
  • Figure 7 is a graphic representation of BMP-2 protein production and alkaline phosphatase activity when bone cells are exposed to a 50% duty cycle, capacitively coupled signal (20 mN/cm, 60 kHz, sine wave) for 24 hours. As indicated, there was a 1.9 fold increase in BMP-2 production and a 1/6 fold increase in alkaline phosphatase activity.
  • Figure 8 is a diagram illustrating a device for up-regulating the gene expression of bone morphogenetic protein, in accordance with an exemplary embodiment of the present invention.
  • the present invention is based on the discovery that the expression of certain genes can be regulated by the application of fields generated by specific and selective electric and/or electromagnetic signals.
  • the present inventors that there is a specific electric and/or electromagnetic signal that generates a field for regulating each gene in bone, cartilage and other tissue cells and that these specific signals are capable of specifically and selectively regulating the genes in such cells.
  • gene expression governing the growth, maintenance, repair, and degeneration or deterioration of tissues or cells can be regulated in accordance with the invention via the application of fields generated by specific and selective electric and/or electromagnetic signals so as to produce a salutary clinical effect.
  • Such discoveries are useful in the development of treatment methods that target certain medical conditions including fresh bone fractures, fractures at risk, delayed union, nonunion, bone defects, osteonecrosis, as an adjunct in the treatment of any one or more of the above, and in the treatment of osteoporosis.
  • the phrase "signal” is used to refer to a variety of signals including mechanical signals, ultrasound signals, electromagnetic signals and electric signals output by a device. It is to be understood that the term “field” as used herein refers to an electrical field within targeted tissue, whether it is a combined field or a pulsed electromagnetic field or generated by direct current, capacitive coupling or inductive coupling. [0027]
  • the phrase “remote” is used to mean acting, acted on or controlled from a distance.
  • Remote regulation refers to controlling the expression of a gene from a distance.
  • To provide “remotely” refers to providing from a distance. For example, providing a specific and selective signal from a remote source can refer to providing the signal from a source at a distance from a tissue or a cell, or from a source outside of or external to the body.
  • the phrase "specific and selective" signal means a signal that produces an electric field that has predetermined characteristics of amplitude, duration, duty cycle, frequency, and waveform that up-regulate or down-regulate a targeted gene or targeted functionally of complementary genes (specificity). This allows one to choose different "specific and selective" signals to up-regulate or down-regulate expression of various genes in order to achieve a given biological or therapeutic response (selectivity).
  • tissue refers to an aggregate of cells together with their extracellular substances that form one of the structural materials of a patient. As used herein, the term “tissue” is intended to include muscle and organ tissue, tumor tissue as well as bone or cartilage tissue. Also, the term “tissue” as used herein may also refer to an individual cell.
  • the present invention provides treatment methods and devices that target certain tissues, cells or diseases.
  • the gene expression associated with the repair process in injured or diseased tissues or cells can be regulated by the application of fields generated by electric signals that are specific and selective for the genes to be regulated in the target tissues or cells.
  • Gene expression can be up-regulated or down-regulated by the application of signals that are specific and selective for each gene or each set of complementary genes so as to produce a beneficial clinical effect.
  • a particular specific and selective signal may create an electric field that up-regulates a certain desirable gene expression, while the same or another particular specific and selective signal may create an electric field that down-regulates a certain undesirable gene expression.
  • a certain gene may be up-regulated by a field generated by one particular specific and selective signal and down-regulated by a field generated by another specific and selective signal.
  • the methods and devices of the present invention are based on identifying those signals that generate fields that are specific and selective for the gene expression associated with certain targeted diseased or injured tissue.
  • electricity in its various forms e.g., capacitive coupling, inductive coupling, combined fields
  • the duration of time exposed to electricity can also influence the capability of electricity to specifically and selectively regulate gene expression in targeted tissues or cells in a patient's body.
  • Specific and selective signals may generate electric fields for application to each gene systematically until the proper combination of frequency, amplitude, waveform, duty cycle, and duration is found that provides the desired effect on gene expression.
  • a variety of diseased or injured tissues or disease states can be targeted for treatment because the specificity and selectivity of an electric field for a certain gene expression can be influenced by several factors.
  • an electrical field of appropriate frequency, amplitude, waveform and/or duty cycle can be specific and selective for the expression of certain genes and thus provide for targeted treatments.
  • Temporal factors e.g., duration of time exposed to the electrical field
  • the regulation of gene expression may be more effective (or made possible) via the application of an electrical field for a particular duration of time.
  • the present invention provides for varying the frequency, amplitude, waveform, duty cycle and/or duration of application of an electric field until the electric field is found to be specific and selective for certain gene expressions in order to provide for treatments targeting a variety of diseased or injured tissue or diseases.
  • the present invention can provide for targeted treatments because it is possible to regulate expression of certain genes associated with a particular diseased or injured tissue via the application of fields generated by specific and selective signals of appropriate frequency, amplitude, wavefonn and/or duty cycle for an appropriate duration of time.
  • the specificity and selectivity of a signal generating an electrical field may thus be influenced so as to regulate the expression of certain genes in order to target certain diseased or injured tissue or disease states for treatment.
  • the present invention provides for the targeted treatment of fresh bone fractures, fractures at risk, nonunion, bone defects, spine fusion, osteonecrosis, as an adjunct in the treatment of one or any of the above, and in the treatment of osteoporosis.
  • the present invention also provides a device that includes a source of at least one signal specific and selective for BMP gene expression.
  • the devices of the present invention can provide for the production of such signals for application to bone cells by at least one electrode adapted to apply the field generated by the specific and selective signal.
  • the devices of the present invention are capable of applying a field generated by specific and selective signals directly to diseased or injured tissue, bone and/or to the skin of a patient.
  • the devices of the present invention may also provide for the remote application of specific and selective fields (e.g., application of a field at a distance from diseased or injured tissue), although it will be appreciated that capacitively coupled devices must touch the subject's skin.
  • the devices of the present invention may include means for attaching the electrodes to the body of a patient in the vicinity of injured or diseased tissue in the case of capacitive coupling.
  • self-adherent conductive electrodes may be attached to the skin of the patient on both sides of a fractured bone 18 or joint 20.
  • the device of the present invention may include self-adherent electrodes for attaching the device to the body of a patient.
  • the device 10 of the present invention may include electrodes 12 attached to a power unit 14 that has a NELCRO ® patch 16 on the reverse side such that the power unit 14 can be attached to a NELCRO ® strap (not shown) fitted around a cast on the patient, hi the case of inductive coupling, the device of the present invention may include coils or solenoids connected to a power unit in place of electrodes.
  • the device 10 of the present invention can be employed in a variety of ways.
  • the device 10 may be portable or may be temporarily or permanently attached to a patient's body.
  • the device 10 of the present invention is preferably non-invasive.
  • the device 10 of the present invention may be applied to the skin of a patient by application of electrodes 12 adapted for contact with the skin of a patient for the application of fields generated by the predetermined specific and selective signals.
  • Such signals may also be applied via coils or solenoids (not shown) in which time varying currents flow, thus producing specific and selective electromagnetic fields that penetrate the tissue.
  • the device 10 of the present invention may also be capable of implantation in a patient, including implantation under the skin for direct contact with the bone of a patient.
  • the devices of the present invention can be provided in a variety of forms including a capacitively coupled power unit with programmed, multiple, switchable, specific and selective signals for application to one pair or to multiple pairs of electrodes, or electromagnetic coils or a solenoid attached to a power unit with switchable, multiple, specific and selective signals, and an ultrasound stimulator with a power supply for generating specific and selective signals.
  • device preference is based on patient acceptance and patient compliance.
  • the smallest and most portable unit available in the art at the present time is a capacitive coupling unit; however, patients with extremely sensitive skin may prefer to use inductive coupling units.
  • ultrasound units require the most patient cooperation, but may be desirable for use by certain patients.
  • MC3T3-E1 bone cells (5 x 10 5 cells/cm 2 ) were plated onto specially-modified Cooper dishes. The cells were grown to seven days with the medium changed just prior to beginning of the experimental condition. The experimental cell cultures throughout these studies were subjected to a capacitively coupled 60 kHz sine wave signal electric field with an output amplitude of 44.81 N peak-to-peak. This produced a calculated-field strength in the culture medium in the dishes of 20 mN/cm with a current density of 300 ⁇ A/cm 2 . Control cell culture dishes were l ⁇ e ⁇ ticaft those 'of the ' stimulated dishes except that the electrodes were not connected to a function generator.
  • BMP up-regulation of
  • An electrical signal known to increase (or even just suspected to increase) cellular production of a given protein is taken as the starting signal for determining the specific signal for generating the field for the gene expression (mRNA) of that protein.
  • a dose-response curve is first performed by varying the duration of the signal while holding all the other signal characteristics constant (amplitude, duty cycle, frequency, and waveform) ( Figure 1). This determines the optimal duration of the starting signal for the gene expression of that protein. As indicated in Figure 1, the maximum expression for the various BMP mRNAs occurred with a signal duration of 24 hours.
  • a second dose-response curve is then performed, this time varying the amplitude of the electric field (in mV/cm) while holding the optimal duration and other signal characteristics constant ( Figure 2).
  • the maximum expression for the various BMP mRNAs occuned with a field amplitude of 20 mN/cm.
  • a third dose response is performed, this time varying the signal frequency while holding constant the optimal duration and optimal amplitude as found previously ( Figure 3).
  • the maximum expression for the various BMP mR ⁇ As occurred with a frequency of 60 kHz.
  • a fourth dose-response is performed varying the duty cycle from 100% (constant) to 10% or less while holding constant the optimal duration, amplitude, and frequency as found previously ( Figure 4).
  • the maximum expression for the various BMP mR ⁇ As occurred with a 50%o duty cycle.
  • a fifth dose-response is performed varying the time OFF/time ON parameters while keeping the duty cycle at 50% and the amplitude and frequency at 20 mN/cm and 60 kHz, respectively, as previously found ( Figure 5).
  • a final experiment is performed to demonstrate an increase in production of the BMP mR ⁇ A product — namely, BMP-2 protein — as well as an increase alkaline phosphatase activity that can be induced by BMP-2 levels.
  • BMP-2 protein namely, BMP-2 protein
  • alkaline phosphatase activity that can be induced by BMP-2 levels.
  • FIG. 8 illustrates a device 10 in accordance with the present invention that is used to treat a patient with osteoarthritis of the knee.
  • two circular, soft conductive, self- adherent electrodes 12 are placed on the skin on either side of the knee at the level of the joint line 20.
  • the electrodes 12 are attached to a power unit 14 that has a NELCRO® patch 16 on the reverse side such that the power unit 14 can be attached to a NELCRO® strap (not shown) fitted around the calf, thigh or waist.
  • the electrodes 12 may be placed on the skin before the patient goes to bed each evening or any other convenient time. Of course, other suitable types of electrodes 12 may also be used.
  • the power unit 14 is preferably small (e.g., 6-8 ounces) and powered by a standard 9- volt battery to emit a 5-volt peak-to-peak, 6-10 mAmp, 20 mN/cm, 60 kHz sine wave signal to the electrodes 12 placed on the skin.
  • this signal is provided approximately 24 hours per day with the proper duty cycle (50%) in 1 minute ON and 1 minute OFF increments, it has been shown to significantly up-regulate genes encoding BMP.
  • the present invention clearly shows that the optimal electric field described in the example can very significantly up-regulate BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7 mRNA and, hence, increase bone formation.
  • an appropriate electric field, as described herein with capacitive coupling is also equally effective with inductive coupling and all electromagnetic systems that produce equivalent, or nearly equivalent, electric field characteristics.
  • more unique signal characteristics may be discovered through more experimentation with more data points (e.g., a 100 ⁇ 3% duty cycle for 30 ⁇ 3 min), but such relatively minor variations in each of the signal characteristics are believed to be within the level of those skilled in the art given the teachings herein.
  • the optimal field described herein can be applied to any bone via two or more appropriate surface electrodes, in pairs or strips, incorporated in braces, wraps, or casts, and delivered by means of capacitive coupling.
  • the optimal field described here can be applied to any bone via coil(s) or solenoid incorporated into braces, wraps, or casts, and delivered by means of inductive coupling. Accordingly, the scope of the invention is not intended to be limited to the prefened embodiment described above, but only by the appended claims.

Abstract

Methods and devices are described for the regulation of bone morphogenetic protein gene expression in bone cells via the application of fields generated by specific and selective electric and electromagnetic signals in the treatment of diseased or injured bone. By gene expression is meant the up-regulation or down-regulation of the process whereby specific portions (genes) of the human genome (DNA) are transcribed into mRNA and subsequently translated into protein. Methods and devices are provided for the targeted treatment of injured or diseased bone tissue that include generating specific and selective electric and electromagnetic signals that generate fields optimized for increase of bone morphogenetic protein gene expression and exposing bone to the fields generated by specific and selective signals so as to regulate bone morphogenetic protein gene expression in such bone tissue. The resulting methods and devices are useful for the targeted treatment of bone fractures, fractures at risk, delayed unions, nonunion of fractures, bone defects, spine fusions, osteonecrosis or avascular necrosis, as an adjunct to other therapies in the treatment of one or all of the above, and in the treatment of osteoporosis.

Description

SYSTEM AND METHOD OF UP-REGULATING BONE MORPHOGENETIC PROTEIN (BMP) GENE EXPRESSION IN BONE CELLS VIA THE APPLICATION OF FIELDS GENERATED BY SPECIFIC AND SELECTIVE ELECTRIC AND ELECTROMAGNETIC SIGNALS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present patent application is a continuation-in-part patent application of U.S. Patent Application Serial No. 10/257,126, which is the U.S. national phase patent application of PCT/US01/05991, filed February 23, 2001, which, in turn, claims the benefit of the filing date of U.S. Provisional Patent Application Serial No. 60/184,491, filed February 23, 2000. The present patent application also claims priority from U.S. Provisional Patent Application No. 60/535,755 filed January 12, 2004. The contents of these patent applications are hereby incorporated by reference in their entireties.
FIELD OF THE INVENTION
[0002] The present invention is directed to a method of up-regulating bone morphogenetic protein (BMP) gene expression in bone cells via the application of fields generated by specific and selective electric and electromagnetic signals for the treatment of injured or diseased bone, as well as devices for generating such signals.
BACKGROUND OF THE INVENTION
[0003] The bioelectrical interactions and activity believed to be present in a variety of biological tissues and cells are one of the least understood of the physiological processes. However, there Has recently been much research into these interactions and activity regarding the growth and repair of certain tissues and cells. In particular, there has been much research into stimulation by electric and electromagnetic fields and its effect on the growth and repair of bone and cartilage. Researchers believe that such research might be useful in the development of new treatments for a variety of medical problems.
[0004] i the disease commonly known as osteoporosis, bone demineralizes and becomes abnormally rarefied. Bone comprises an organic component of cells and matrix as well as an inorganic or mineral component. The cells and matrix comprise a framework of collagenous fibers that is impregnated with the mineral component of calcium phosphate (85%) and calcium carbonate (10%) that imparts rigidity to the bone. While osteoporosis is generally thought as afflicting the elderly, certain types of osteoporosis may affect persons of all ages whose bones are not subject to functional stress. In such cases, patients may experience a significant loss of cortical and cancellous bone during prolonged periods of immobilization. Elderly patients are known to experience bone loss due to disuse when immobilized after fracture of a bone, and such bone loss may ultimately lead to a secondary fracture in an already osteoporotic skeleton. Diminished bone density may lead to vertebrae collapse, fractures of hips, lower arms, wrists, ankles as well as incapacitating pains. Alternative nonsurgical therapies for such diseases are needed.
[0005] Pulsed electromagnetic fields (PEMF) and capacitive coupling (CC) have been used widely to treat nonhealing fractures (nonunion) and related problems in bone healing since approval by the Food and Drug Administration in 1979. The original basis for the trial of this form of therapy was the observation that physical stress on bone causes the appearance of tiny electric currents that, along with mechanical strain, were thought to be the mechanisms underlying transduction of the physical stresses into a signal that promotes bone formation. Along with direct electric field stimulation that was successful in the treatment of nonunion, noninvasive technologies using PEMF and capacitive coupling (where the electrodes are placed on the skin in the treatment zone) were also found to be effective. PEMFs generate small, induced currents (Faraday currents) in the highly-conductive extracellular fluid, while capacitive coupling directly causes currents in the tissues; both PEMFs and CC thereby mimic endogenous electrical currents.
[0006] The endogenous electrical currents, originally thought to be due to phenomena occurring at the surface of crystals in the bone, have been shown to be due primarily to movement of fluid containing electrolytes in channels of the bone containing organic constituents with fixed negative charges, generating what are called "streaming potentials." Studies of electrical phenomena in bone have demonstrated a mechanical-electrical transduction mechanism that appears when bone is mechanically compressed, causing movement of fluid and electrolytes over the surface of fixed negative charges in the proteoglycans and collagen in the bone matrix. These streaming potentials serve a purpose in bone, and, along with mechanical strain, lead to signal transduction that is capable of stimulating bone cell synthesis of a calcifiable matrix, and, hence, the formation of bone.
[0007] The main application of direct current, capacitive coupling, and PEMFs has been in orthopedics in healing of nonunion bone fractures (Brighton et al., J. Bone Joint Surg. 63: 2-13, 1981; Brighton and Pollack, J. Bone Joint Surg. 67: 577-585, 1985; Bassett et al., Crit. Rev. Biorned. Eng. 17: 451-529, 1989; Bassett et al., JAMA 247: 623-628, 1982). Clinical responses have been reported in avascular necrosis of hips in adults and Legg-Perthes's disease in children (Bassett et al., Clin. Orthop. 246: 172-176, 1989; Aaron et al., Clin. Orthop. 249: 209-218, 1989; Harrison et al., J Pediatr. Orthop. 4: 579-584, 1984). It has also been shown that PEMFs (Mooney, Spine 15: 708-712, 1990) and capacitive coupling (Goodwin, Brighton et al., Spine 24: 1349-1356, 1999) can significantly increase the success rate of lumbar fusions. There are also reports of augmentation of peripheral nerve regeneration and function and promotion of angiogenesis (Bassett, Bioessays 6: 36-42, 1987). Patients with persistent rotator cuff tendonitis refractory to steroid injection and other conventional measures, showed significant benefit compared with placebo-treated patients (Binder et al., Lancet 695-698, 1984). Finally, Brighton et al. have shown in rats the ability of an appropriate capacitive coupling electric field to both prevent and reverse vertebral osteoporosis in the lumbar spine (Brighton et al., J Orthop. Res. 6: 676-684, 1988; Brighton et al, J. Bone Joint Surg. 71 : 228-236, 1989).
[0008] More recently, research in this area has focused on the effects stimulation has on tissues and cells. For example, it has been conjectured that direct currents do not penetrate cellular membranes, and that control is achieved via extracellular matrix differentiation (Grodzinsky, Crit. Rev. Biorned. Eng. 9:133-199, 1983). In contrast to direct currents, it has been reported that PEMFs can penetrate cell membranes and either stimulate them or directly affect intracellular organelles. An examination of the effect of PEMFs on extracellular matrices and in vivo endochondral ossification found increased synthesis of cartilage molecules and maturation of bone trabeculae (Aaron et al., J. Bone Miner. Res. 4: 227-233, 1989). More recently, Lorich et al. (Clin. Orthop. Related Res. 350: 246-256, 1998) and Brighton et al. (J. Bone Joint Surg. 83- A, 1514—1523, 2001) reported that signal transduction of a capacitively coupled electric signal is via voltage gated calcium channels, whereas signal transduction of PEMFs or combined electromagnetic fields is via the release of calcium from intracellular stores. In all three types of electrical stimuratiδh here'ιs"an increase in cytosolic calcium with a subsequent increase in activated (cytoskeletal) calmodulin.
[0009] It was reported in 1996 by the present inventors that a cyclic biaxial 0.17% mechanical strain produces a significant increase in TGF-βi mRNA in cultured MC3T3-E1 bone cells (Brighton et al, Biochem. Biophys. Res. Commun. 229: 449-453, 1996). Several significant studies followed in 1997. In one study it was reported that the same cyclic biaxial 0.17% mechanical strain produced a significant increase in PDGF-A mRNA in similar bone cells (Brighton et al, Biochem. Biophys. Res. Commun. 43: 339-346, 1997). It was also reported that a 60 kHz capacitively coupled electric field of 20 mV/cm produced a significant increase in TGF-βi in similar bone cells (Brighton et al., Biochem. Biophys. Res. Commun. 237: 225-229, 1997). However, the effect such a field would have on other genes has not been reported in the literature.
[0010] In the above-referenced parent patent application, entitled Regulation of Genes Via Application of Specific and Selective Electrical and Electromagnetic Signals, methods were disclosed for determining the specific and selective electrical and electromagnetic signals for use in creating fields for regulating target genes of diseased or injured tissues. The present invention builds upon the technique described therein by describing the method of regulating expression of one targeted gene family, namely, bone morphogenetic protein(s) gene expression, through application of a field generated by a specific and selective electrical and electromagnetic signal, for the treatment of fresh fractures, fractures at risk, delayed unions, nonunion of fractures, bone defects, spine fusions, osteonecrosis or avascular necrosis, as an adjunct to other therapies in the treatment of one or all of the above, and in the treatment of osteoporosis.
SUMMARY OF THE INVENTION
[0011] The present invention relates to regulating bone morphogenetic protein gene expression in bone cells via the application of fields generated by specific and selective electric and/or electromagnetic signals. By performing dose-response curves on the electric field duration, amplitude, frequency, and duty cycle, the optimal signal for up-regulating bone morphogenetic protein mRNA in bone cells was discovered. The optimal signal generated a capacitively coupled electric field with an amplitude of 20 mV/cm, a duration of 24 hours, a frequency of 60 kHz, a duty cycle of 50%, and a sine wave configuration. In particular, the present invention relates to up-regulating bone morphogenetic protein (BMP) gene expression in bone cells via the application of fields generated by such signals.
[0012] In accordance with the invention, methods are provided to specifically and selectively up-regulate the gene expression (as measured by mRNA) of BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7, with capacitively coupled electric fields, electromagnetic fields, or combined fields. Fresh fractures, fractures at risk, delayed unions, nonunion fractures, bone defects, osteonecrosis, osteoporosis, and the like are treated with a capacitively coupled electric field of about 20 mN/cm with an electric field duration of about 24 hours, a frequency of 60 kHz, a duty cycle of about 50%, and a sine wave configuration that causes the expression of BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7 rnRΝAs to be up-regulated. In accordance with the method of the invention, a "specific and selective" signal is a signal that has predetermined characteristics of amplitude, duration, duty-cycle, frequency, and waveform that up-regulates the expression of the BMP genes (specificity). This allows one to choose different signals to up-regulate BMP gene expressions in order to achieve a given biological or therapeutic response (selectivity). The invention further relates to devices employing the methods described herein to generate specific and selective signals that create fields to up-regulate the expression of BMP genes. [0013] h related aspects, the present invention relates to methods and devices for the treatment of fresh fractures, fractures at risk, delayed unions, nonunions, bone defects, spine fusion, osteonecrosis, as an adjunct to other therapies treating one or more of the above, and in the treatment of osteoporosis. The method of the invention also includes the methodology for determining the "specific and selective" signal for BMP gene expression by methodically varying the duration of a starting signal known to increase, or suspected to increase, cellular production of BMPs. After finding the optimal duration, the amplitude of the signal is varied for the optimal duration of time as determined by the gene expression of BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7. The duty cycle, frequency, and waveform are varied methodically in the same dose response manner as above while keeping the other signal characteristics constant. This process is repeated until the optimal signal is determined that produces the greatest increase in the expression of BMPs.
[0014] These and other aspects of the present invention will be elucidated in the following detailed description of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0015] The present invention will be apparent from the following detailed description of the invention taken in conjunction with the accompanying drawings, of which: [0016] Figure 1 is a graphic representation of the mRNA expression of BMP-2, BMP-4, BMP- 5, BMP-6, and BMP-7 when bone cells are exposed to a 20 mN/cm capacitively coupled electric field for various time durations. As indicated, the maximum expression for the various BMP mRΝAs occurred with a signal of 24 hours duration. [0017] Figure 2 is a graphic representation of mRNA expression of BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7 when bone cells are exposed to various capacitively coupled electric field amplitudes with a duration of 24 hours. As indicated, the maximum expression for the various BMP mRNAs occurred with a field amplitude of 20 mN/cm.
[0018] Figure 3 is a graphic representation of mRNA expression of BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7 when bone cells are exposed to various capacitively coupled electric field frequencies with a field amplitude of 20 mV/cm and a signal duration of 24 hours. As indicated, the maximum expression for the various BMP mRNAs occurred with a frequency of 60 kHz. [0019] Figure 4 is a graphic representation of mRNA expression of BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7 when bone cells are exposed to various capacitively coupled electric field duty cycles with a frequency of 60 kHz, a field amplitude of 20 mN/cm, and a signal duration of 24 hours. As indicated, the maximum expression for the various BMP rnRΝAs occurred with a 50% duty cycle.
[0020] Figure 5 is a graphic representation of mR A expression of BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7 when bone cells are exposed to a capacitively coupled electric field of a 50% duty cycle of various on-off times with a field amplitude of 20 mN/cm and a frequency of 60 kHz. As indicated, the maximum expression for the various BMP mRΝAs occurred with a 1 minute ON / 1 minute OFF 50% duty cycle.
[0021] Figure 6 is a graphic representation of BMP-2 mRNA expression when bone cells are exposed to a capacitively coupled continuous 50% duty cycle signal (20 mV/cm, 60 kHz, sine wave) versus a pulsed 50% duty cycle signal. As indicated, both signals showed essentially the same five- fold increase in BMP-2 mRNA.
[0022] Figure 7 is a graphic representation of BMP-2 protein production and alkaline phosphatase activity when bone cells are exposed to a 50% duty cycle, capacitively coupled signal (20 mN/cm, 60 kHz, sine wave) for 24 hours. As indicated, there was a 1.9 fold increase in BMP-2 production and a 1/6 fold increase in alkaline phosphatase activity. [0023] Figure 8 is a diagram illustrating a device for up-regulating the gene expression of bone morphogenetic protein, in accordance with an exemplary embodiment of the present invention.
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
[0024] The invention will be described in detail below with reference to Figures 1-8. Those skilled in the art will appreciate that the description given herein with respect to those figures is for exemplary purposes only and is not intended in any way to limit the scope of the invention.
All questions regarding the scope of the invention may be resolved by referring to the appended claims. [0025] The present invention is based on the discovery that the expression of certain genes can be regulated by the application of fields generated by specific and selective electric and/or electromagnetic signals. In other words, it has been discovered by the present inventors that there is a specific electric and/or electromagnetic signal that generates a field for regulating each gene in bone, cartilage and other tissue cells and that these specific signals are capable of specifically and selectively regulating the genes in such cells. In particular, gene expression governing the growth, maintenance, repair, and degeneration or deterioration of tissues or cells can be regulated in accordance with the invention via the application of fields generated by specific and selective electric and/or electromagnetic signals so as to produce a salutary clinical effect. Such discoveries are useful in the development of treatment methods that target certain medical conditions including fresh bone fractures, fractures at risk, delayed union, nonunion, bone defects, osteonecrosis, as an adjunct in the treatment of any one or more of the above, and in the treatment of osteoporosis.
[0026] As used herein, the phrase "signal" is used to refer to a variety of signals including mechanical signals, ultrasound signals, electromagnetic signals and electric signals output by a device. It is to be understood that the term "field" as used herein refers to an electrical field within targeted tissue, whether it is a combined field or a pulsed electromagnetic field or generated by direct current, capacitive coupling or inductive coupling. [0027] The phrase "remote" is used to mean acting, acted on or controlled from a distance. "Remote" regulation refers to controlling the expression of a gene from a distance. To provide "remotely" refers to providing from a distance. For example, providing a specific and selective signal from a remote source can refer to providing the signal from a source at a distance from a tissue or a cell, or from a source outside of or external to the body.
[0028] The phrase "specific and selective" signal means a signal that produces an electric field that has predetermined characteristics of amplitude, duration, duty cycle, frequency, and waveform that up-regulate or down-regulate a targeted gene or targeted functionally of complementary genes (specificity). This allows one to choose different "specific and selective" signals to up-regulate or down-regulate expression of various genes in order to achieve a given biological or therapeutic response (selectivity).
[0029] The term "regulate" means to control gene expression. Regulate is understood to include both up-regulate and down-regulate. Up-regulate means to increase expression of a gene, while down-regulate means to inhibit or prevent expression of a gene. [0030] "Functionally complementary" refers to two or more genes whose expressions are complementary or synergistic in a given cell or tissue. [0031] "Tissue" refers to an aggregate of cells together with their extracellular substances that form one of the structural materials of a patient. As used herein, the term "tissue" is intended to include muscle and organ tissue, tumor tissue as well as bone or cartilage tissue. Also, the term "tissue" as used herein may also refer to an individual cell.
[0032] "Patient" refers to an animal, preferably a mammal, more preferably a human. [0033] The present invention provides treatment methods and devices that target certain tissues, cells or diseases. In particular, the gene expression associated with the repair process in injured or diseased tissues or cells can be regulated by the application of fields generated by electric signals that are specific and selective for the genes to be regulated in the target tissues or cells. Gene expression can be up-regulated or down-regulated by the application of signals that are specific and selective for each gene or each set of complementary genes so as to produce a beneficial clinical effect. For example, a particular specific and selective signal may create an electric field that up-regulates a certain desirable gene expression, while the same or another particular specific and selective signal may create an electric field that down-regulates a certain undesirable gene expression. A certain gene may be up-regulated by a field generated by one particular specific and selective signal and down-regulated by a field generated by another specific and selective signal. Those skilled in the art will understand that certain diseased or injured tissues can be targeted for treatment by regulating those genes governing the growth, maintenance, repair, and degeneration or deterioration of the tissues.
[0034] The methods and devices of the present invention are based on identifying those signals that generate fields that are specific and selective for the gene expression associated with certain targeted diseased or injured tissue. For example, electricity in its various forms (e.g., capacitive coupling, inductive coupling, combined fields) can specifically and selectively regulate gene expression in targeted tissues or cells in a patient's body by varying the frequency, amplitude, wavefonn or duty cycle of the applied field for each selected gene. The duration of time exposed to electricity can also influence the capability of electricity to specifically and selectively regulate gene expression in targeted tissues or cells in a patient's body. Specific and selective signals may generate electric fields for application to each gene systematically until the proper combination of frequency, amplitude, waveform, duty cycle, and duration is found that provides the desired effect on gene expression.
[0035] It is to be understood that a variety of diseased or injured tissues or disease states can be targeted for treatment because the specificity and selectivity of an electric field for a certain gene expression can be influenced by several factors. In particular, an electrical field of appropriate frequency, amplitude, waveform and/or duty cycle can be specific and selective for the expression of certain genes and thus provide for targeted treatments. Temporal factors (e.g., duration of time exposed to the electrical field) can also influence the specificity and selectivity of an electric field for a particular gene expression. The regulation of gene expression may be more effective (or made possible) via the application of an electrical field for a particular duration of time. Therefore, those skilled in the art will understand that the present invention provides for varying the frequency, amplitude, waveform, duty cycle and/or duration of application of an electric field until the electric field is found to be specific and selective for certain gene expressions in order to provide for treatments targeting a variety of diseased or injured tissue or diseases.
[0036] Thus, the present invention can provide for targeted treatments because it is possible to regulate expression of certain genes associated with a particular diseased or injured tissue via the application of fields generated by specific and selective signals of appropriate frequency, amplitude, wavefonn and/or duty cycle for an appropriate duration of time. The specificity and selectivity of a signal generating an electrical field may thus be influenced so as to regulate the expression of certain genes in order to target certain diseased or injured tissue or disease states for treatment. In particular, the present invention provides for the targeted treatment of fresh bone fractures, fractures at risk, nonunion, bone defects, spine fusion, osteonecrosis, as an adjunct in the treatment of one or any of the above, and in the treatment of osteoporosis. [0037] The present invention also provides a device that includes a source of at least one signal specific and selective for BMP gene expression. The devices of the present invention can provide for the production of such signals for application to bone cells by at least one electrode adapted to apply the field generated by the specific and selective signal. [0038] The devices of the present invention are capable of applying a field generated by specific and selective signals directly to diseased or injured tissue, bone and/or to the skin of a patient. The devices of the present invention may also provide for the remote application of specific and selective fields (e.g., application of a field at a distance from diseased or injured tissue), although it will be appreciated that capacitively coupled devices must touch the subject's skin. The devices of the present invention may include means for attaching the electrodes to the body of a patient in the vicinity of injured or diseased tissue in the case of capacitive coupling. For example, as shown in Figure 8, self-adherent conductive electrodes may be attached to the skin of the patient on both sides of a fractured bone 18 or joint 20. The device of the present invention may include self-adherent electrodes for attaching the device to the body of a patient. For example, the device 10 of the present invention may include electrodes 12 attached to a power unit 14 that has a NELCRO® patch 16 on the reverse side such that the power unit 14 can be attached to a NELCRO® strap (not shown) fitted around a cast on the patient, hi the case of inductive coupling, the device of the present invention may include coils or solenoids connected to a power unit in place of electrodes.
[0039] The device 10 of the present invention can be employed in a variety of ways. The device 10 may be portable or may be temporarily or permanently attached to a patient's body. The device 10 of the present invention is preferably non-invasive. For example, the device 10 of the present invention may be applied to the skin of a patient by application of electrodes 12 adapted for contact with the skin of a patient for the application of fields generated by the predetermined specific and selective signals. Such signals may also be applied via coils or solenoids (not shown) in which time varying currents flow, thus producing specific and selective electromagnetic fields that penetrate the tissue. The device 10 of the present invention may also be capable of implantation in a patient, including implantation under the skin for direct contact with the bone of a patient.
[0040] Those skilled in the art will further understand that the devices of the present invention can be provided in a variety of forms including a capacitively coupled power unit with programmed, multiple, switchable, specific and selective signals for application to one pair or to multiple pairs of electrodes, or electromagnetic coils or a solenoid attached to a power unit with switchable, multiple, specific and selective signals, and an ultrasound stimulator with a power supply for generating specific and selective signals. Generally speaking, device preference is based on patient acceptance and patient compliance. The smallest and most portable unit available in the art at the present time is a capacitive coupling unit; however, patients with extremely sensitive skin may prefer to use inductive coupling units. On the other hand, ultrasound units require the most patient cooperation, but may be desirable for use by certain patients. Example
[0041] The invention is demonstrated in the following example, which is for purposes of illustration and is not intended to limit the scope of the present invention. Materials and Methods
[0042] MC3T3-E1 bone cells (5 x 105 cells/cm2) were plated onto specially-modified Cooper dishes. The cells were grown to seven days with the medium changed just prior to beginning of the experimental condition. The experimental cell cultures throughout these studies were subjected to a capacitively coupled 60 kHz sine wave signal electric field with an output amplitude of 44.81 N peak-to-peak. This produced a calculated-field strength in the culture medium in the dishes of 20 mN/cm with a current density of 300 μA/cm2. Control cell culture dishes were lαeήticaft those 'of the' stimulated dishes except that the electrodes were not connected to a function generator.
[0043] At the end of the experiment, total RNA was isolated using TRIzol, according to the manufacturer's instructions, and reversed transcription (RT) using Superscript II reverse transcriptase was performed. Oligonucleotide primers to be used in the real time RT-PCR technique were selected from published cDNA sequences or designed using the Primer Express software program. Quantitative real-time analysis of RT-PCR products was performed using an ABI Prism® 7000 Sequence Detection System. [0044] The optimal signal for the desired up-regulation of (BMP) genes — including genes for BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7, among others— was found systematically as follows. An electrical signal known to increase (or even just suspected to increase) cellular production of a given protein (e.g., 60 kHz sine wave) is taken as the starting signal for determining the specific signal for generating the field for the gene expression (mRNA) of that protein. A dose-response curve is first performed by varying the duration of the signal while holding all the other signal characteristics constant (amplitude, duty cycle, frequency, and waveform) (Figure 1). This determines the optimal duration of the starting signal for the gene expression of that protein. As indicated in Figure 1, the maximum expression for the various BMP mRNAs occurred with a signal duration of 24 hours. A second dose-response curve is then performed, this time varying the amplitude of the electric field (in mV/cm) while holding the optimal duration and other signal characteristics constant (Figure 2). As indicated, the maximum expression for the various BMP mRNAs occuned with a field amplitude of 20 mN/cm. A third dose response is performed, this time varying the signal frequency while holding constant the optimal duration and optimal amplitude as found previously (Figure 3). As indicated, the maximum expression for the various BMP mRΝAs occurred with a frequency of 60 kHz. A fourth dose-response is performed varying the duty cycle from 100% (constant) to 10% or less while holding constant the optimal duration, amplitude, and frequency as found previously (Figure 4). As indicated, the maximum expression for the various BMP mRΝAs occurred with a 50%o duty cycle. Finally, a fifth dose-response is performed varying the time OFF/time ON parameters while keeping the duty cycle at 50% and the amplitude and frequency at 20 mN/cm and 60 kHz, respectively, as previously found (Figure 5). As indicated, the maximum expression for the various BMP mR As occurred with a 1 minute ON / 1 minute OFF 50% duty cycle.
[0045] By this method, an optimal signal is determined for producing the greatest increase in the gene expression of the various BMPs. [0046] A sixth experiment is performed comparing a continuous 50% duty cycle (capacitive coupling, 20 mN/cm, 60 kHz sine wave) to a pulsed 50% duty cycle (capacitive coupling, 20 mN/cm, 60 kHz). As indicated, the increase in BMP-2 mRΝA was about 5 fold with each signal (Figure 6).
[0047] A final experiment is performed to demonstrate an increase in production of the BMP mRΝA product — namely, BMP-2 protein — as well as an increase alkaline phosphatase activity that can be induced by BMP-2 levels. After 24 hours of stimulation with a 50% duty cycle (capacitively coupled, 20 mN/cm, 60 kHz, sine wave) signal, there was a 1.9-fold and 1.6-fold increase in BMP-2 product and alkaline phosphatase activity, respectively (Figure 7).
[0048] Figure 8 illustrates a device 10 in accordance with the present invention that is used to treat a patient with osteoarthritis of the knee. As illustrated, two circular, soft conductive, self- adherent electrodes 12 are placed on the skin on either side of the knee at the level of the joint line 20. The electrodes 12 are attached to a power unit 14 that has a NELCRO® patch 16 on the reverse side such that the power unit 14 can be attached to a NELCRO® strap (not shown) fitted around the calf, thigh or waist. The electrodes 12 may be placed on the skin before the patient goes to bed each evening or any other convenient time. Of course, other suitable types of electrodes 12 may also be used.
[0049] The power unit 14 is preferably small (e.g., 6-8 ounces) and powered by a standard 9- volt battery to emit a 5-volt peak-to-peak, 6-10 mAmp, 20 mN/cm, 60 kHz sine wave signal to the electrodes 12 placed on the skin. When this signal is provided approximately 24 hours per day with the proper duty cycle (50%) in 1 minute ON and 1 minute OFF increments, it has been shown to significantly up-regulate genes encoding BMP.
[0050] The present invention clearly shows that the optimal electric field described in the example can very significantly up-regulate BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7 mRNA and, hence, increase bone formation. Those skilled in the art will appreciate that an appropriate electric field, as described herein with capacitive coupling, is also equally effective with inductive coupling and all electromagnetic systems that produce equivalent, or nearly equivalent, electric field characteristics. Those skilled in the art will also appreciate that more unique signal characteristics may be discovered through more experimentation with more data points (e.g., a 100 ± 3% duty cycle for 30 ± 3 min), but such relatively minor variations in each of the signal characteristics are believed to be within the level of those skilled in the art given the teachings herein.
[0051] Those skilled in the art will also appreciate that numerous other modifications to the invention are possible within the scope of the invention. For example, the optimal field described herein can be applied to any bone via two or more appropriate surface electrodes, in pairs or strips, incorporated in braces, wraps, or casts, and delivered by means of capacitive coupling. Also, the optimal field described here can be applied to any bone via coil(s) or solenoid incorporated into braces, wraps, or casts, and delivered by means of inductive coupling. Accordingly, the scope of the invention is not intended to be limited to the prefened embodiment described above, but only by the appended claims.

Claims

What is Claimed:
1. A method of specifically and selectively up-regulating the gene expression of bone morphogenetic protein(s) in tissue, comprising the steps of: a. generating at least one specific and selective signal that has signal characteristics that are selected to up-regulate the gene expression of bone morphogenetic protein(s) (BMPs) as measured by mRNA when said signal is applied to the tissue; and b. exposing the bone tissue to a field generated by the specific and selective signal for a predetermined duration of time at predetennined intervals so as to up-regulate the expression of BMPs as measured by mRNA.
2. The method of claim 1 wherein the generating step comprises the step of selectively varying the amplitude, duration, duty cycle, frequency, and waveform of the specific and selective signal until the up-regulation of the gene expression of BMPs as measured by mRNA in bone tissue by the generated field is substantially increased.
3. The method of claim 1 wherein said generating step comprises the step of generating the specific and selective signal at a remote source and said exposing step comprises the step of applying the field generated by the specific and selective signal to the bone tissue.
4. The method of claim 3 wherein the exposing step comprises the step of applying the specific and selective signal to electrodes, coil(s) or a solenoid located near the bone tissue.
5. The method of claim 4 wherein the exposing step comprises the step of applying the field generated by the specific and selective signal to the bone tissue through one of capacitive coupling and inductive coupling.
6. The method of claim 5 wherein the specific and selective signal causes the electrodes to generate one of a capacitive coupling electric field and the coil(s) or solenoid to generate an electromagnetic field or a combined field.
7. A method for treating at least one of a bone fracture, fracture at risk, delayed union, nonunion, bone defect, spine fusion, osteonecrosis, and osteoporosis, comprising the steps of: a. generating at least one specific and selective signal that up-regulates the gene expression" of hone morph6gehetic'protein(s) as measured by mRNA; and b. exposing bone tissue to a field generated by the specific and selective signal for a predetermined duration at predetermined intervals so as to selectively up-regulate gene expression of bone morphogenetic protein as measured by mRNA.
8. The method of claim 7 wherein the exposing step comprises the step of capacitively coupling the field to bone tissue.
9. The method of claim 7 wherein the exposing step comprises the step of applying one of an electromagnetic field and a combined field to bone tissue.
10. The method of claim 7 wherein the generating step comprises the step of generating an electric field having an amplitude of approximately 20 mN/cm, a sine wave configuration, a duty cycle of approximately 50%, and a frequency of approximately 60 kHz.
11. The method of claim 10 wherein the exposing step comprises the step of applying the electric field to the bone tissue for a duration of approximately 24 hours every 24 hours.
12. The method of claim 11 wherein the exposing step comprises the step of applying the electric field to the bone tissue for a 50% duty cycle of 1 minute ON and 1 minute OFF.
13. The method of claim 7 wherein the generating step comprises the steps of selectively varying the amplitude, duration, duty cycle, frequency, and waveform of the specific and selective signal until the up-regulation of the gene expression of bone morphogenetic protein(s) as measured by mRNA in the bone tissue by the generated field is substantially increased.
14. The method of claim 13 wherein the exposing step comprises the step of applying the field generated by the specific and selective signal to the bone tissue through one of capacitive coupling and inductive coupling.
15. The method of claim 14 wherein the specific and selective signal causes electrodes applied to the patient's skin to generate one of a capacitive coupling electric field, an electromagnetic field, and a combined field.
16. A device for the treatment of at least one of bone fractures, fractures at risk, delayed unions, nonunions, bone defects, spine fusion, osteonecrosis, and osteoporosis, comprising a signal source that provides at least one signal that creates a field specific and selective for up-regulating gene expression of bone moφhogenetic protein(s) as measured by mRNA, and electrodes or coil(s) connected to the signal source that receive said at least one specific and selective signal for application of the field to the bone tissue for a predetermined duration at predetermined intervals so as to selectively up-regulate gene expression of bone morphogenetic protein(s) as measured by mRNA in said bone.
17. The device of claim 16 further comprising a portable power unit that drives said signal source.
18. The device of claim 16 further comprising means for attaching the electrodes to the body of a patient in the vicinity of bone tissue.
19. The device of claim 16 further comprising means for attaching the signal source to the body of a patient.
20. The device of claim 16 wherein the field generated by said at least one specific and selective signal is applied to said bone tissue via one of capacitive coupling and inductive coupling.
21. The device of claim 20 wherein the specific and selective signal has a sine wave configuration and generates an electric field having an amplitude of about 20 mN/cm at 60 kHz with approximately a 50% duty cycle.
22. A method of treating at least one of bone fractures, fractures at risk, delayed unions, nonunions, bone defects, spine fusion, osteonecrosis, and osteoporosis comprising the steps of exposing bone tissue to the specific and selective field generated by the device of claim 21 so as to up-regulate gene expression of bone morphogenetic protein(s) as measured by mRΝA in the bone tissue.
23. The method of claim 22, wherein the exposing step comprises the step of applying the specific"'and seTeMveΛield to the bone tissue for a duration of approximately 24 hours every 24 hours with a 50% duty cycle of 1 minute on and 1 minute off.
24. A method of determining a selective signal that generates an electric field that up- regulates bone morphogenetic protein(s), comprising the steps of selecting a starting signal with a signal shape and frequency known to increase or suspected to affect cellular production of bone morphogenetic protein(s), selectively varying a duration of application of said starting signal until a duration that provides a most significant increase of BMP(s) is found, varying an amplitude of said starting signal until an amplitude that provides a most significant increase of BMP(s) is found, varying a duty cycle of the starting signal until a duty cycle that provides a most significant increase of BMP(s) is found, and varying the duration of an on-off interval of the duty cycle of the signal until an on-off interval that provides a most significant increase of BMP(s) is found.
25. A method as in claim 24, comprising the further steps of selectively varying a frequency and wavefonn of said signal, keeping other signal characteristics constant, until a greatest increase in the gene expression of BMP as measured by mRNA is found.
PCT/US2005/000793 2000-02-23 2005-01-11 Up-regulation of bone morphogenetic protein (bmp) gene expression in bone cells by electromagnetic signals WO2005070136A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
BRPI0506826-6A BRPI0506826A (en) 2004-01-12 2005-01-11 methods for specifically and selectively enhancing gene expression of bone morphogenetic protein (s) in tissue, treatment device and method for determining a selective signal generating an electric field
JP2006549515A JP4801802B2 (en) 2004-01-12 2005-01-11 Systems and methods for upregulating bone morphogenetic protein (BMP) gene expression in bone cells via application of electric fields generated by specific selective electrical and electromagnetic signals
EP05705445A EP1716228A4 (en) 2004-01-12 2005-01-11 System and method of up-regulating bone morphogenetic protein (bmp) gene expression in bone cells via the appplication of fields generated by specific and selective electric and electromagnetic signals
US10/585,718 US8017369B2 (en) 2000-02-23 2005-01-11 System and method of up-regulating bone morphogenetic proteins (BMP) gene expression in bone cells via the application of fields generated by specific and selective electric and electromagnetic signals
CA2553199A CA2553199C (en) 2004-01-12 2005-01-11 System for up-regulating bone morphogenetic protein (bmp) gene expression in bone cells via the application of fields generated by specific electric and electromagnetic signals
KR1020067013999A KR101324824B1 (en) 2004-01-12 2005-01-11 System and method of up-regulating bone morphogenetic protein (bmp) gene expression in bone cells via the application of fields generated by specific and selective electric and electromagnetic signals
CN2005800047115A CN1918285B (en) 2004-01-12 2005-01-11 System and method of up-regulating bone morphogenetic protein (bmp) gene expression in bone cells via the application of fields generated by specific and selective electric and electromagnetic signal
AU2005206794A AU2005206794B2 (en) 2004-01-12 2005-01-11 Up-regulation of bone morphogenetic protein (BMP) gene expression in bone cells by electromagnetic signals
NZ548447A NZ548447A (en) 2004-01-12 2005-01-11 Up-regulation of bone morphogenetic protein (BMP) gene expression in bone cells by electromagnetic signals
IL176783A IL176783A (en) 2004-01-12 2006-07-11 Device for treatment of bone fractures, delayed unions, bone defects, spine fusion osteonecrosis and osteoporosis via application of fields generated by specific and selective electric and electromagnetic signals
NO20063444A NO20063444L (en) 2004-01-12 2006-07-26 System and method for up-regulating bone morphogenetic protein gene expression in bone cells using fields generated by specific and selective electrical and electromagnetic signals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53575504P 2004-01-12 2004-01-12
US60/535,755 2004-01-12

Publications (2)

Publication Number Publication Date
WO2005070136A2 true WO2005070136A2 (en) 2005-08-04
WO2005070136A3 WO2005070136A3 (en) 2005-10-06

Family

ID=34806961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/000793 WO2005070136A2 (en) 2000-02-23 2005-01-11 Up-regulation of bone morphogenetic protein (bmp) gene expression in bone cells by electromagnetic signals

Country Status (14)

Country Link
US (1) US8017369B2 (en)
EP (1) EP1716228A4 (en)
JP (1) JP4801802B2 (en)
KR (1) KR101324824B1 (en)
CN (1) CN1918285B (en)
AU (1) AU2005206794B2 (en)
BR (1) BRPI0506826A (en)
CA (1) CA2553199C (en)
IL (1) IL176783A (en)
NO (1) NO20063444L (en)
NZ (1) NZ548447A (en)
RU (1) RU2388817C2 (en)
WO (1) WO2005070136A2 (en)
ZA (1) ZA200605716B (en)

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022506B2 (en) 2000-02-23 2006-04-04 The Trustees Of The University Of Pennsylvania Method and device for treating osteoarthritis, cartilage disease, defects and injuries in the human knee
US7130692B2 (en) 2000-02-23 2006-10-31 The Trustees Of The University Of Pennsylvania Portable electrotherapy device for treating osteoarthritis and other diseases, defects and injuries of the knee joint
US7158835B2 (en) 2001-12-21 2007-01-02 The Trustees Of The University Of Pennsylvania Device for treating osteoporosis, hip and spine fractures and fusions with electric fields
US7167753B2 (en) 2001-07-03 2007-01-23 The Trustees Of The University Of Pennsylvania Device and method for electrically inducing osteogenesis in the spine
US7215995B2 (en) 2003-11-14 2007-05-08 The Trustees Of The University Of Pennsylvania Method and device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip
US7374916B2 (en) 2000-02-23 2008-05-20 The Trustees Of The University Of Pennsylvania Regulation of aggrecan gene expression using specific and selective electrical and electromagnetic signals
US7429471B2 (en) 2000-02-23 2008-09-30 The Trustees Of The University Of Pennsylvania Regulation of matrix metalloproteinase gene expression using specific and selective electrical and electromagnetic signals
US7465566B2 (en) 2000-02-23 2008-12-16 The Trustees Of The University Of Pennsylvania Regulation of genes via application of specific and selective electrical and electromagnetic signals
US7465546B2 (en) 2000-02-23 2008-12-16 The Trustees Of The University Of Pennsylvania Regulation of transforming growth factor-beta (TGF-β) gene expression in living cells via the application of specific and selective electric and electromagnetic fields
US7981611B2 (en) 2000-02-23 2011-07-19 The Trustees Of The University Of Pennsylvania Regulation of fibroblastic growth factor-2 (FGF-2) gene expression in living cells with the application of specific and selective electric and electromagnetic fields
US8017369B2 (en) 2000-02-23 2011-09-13 The Trustees Of The University Of Pennsylvania System and method of up-regulating bone morphogenetic proteins (BMP) gene expression in bone cells via the application of fields generated by specific and selective electric and electromagnetic signals
US8153606B2 (en) 2008-10-03 2012-04-10 Opko Curna, Llc Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
US8288354B2 (en) 2005-12-28 2012-10-16 The Scripps Research Institute Natural antisense and non-coding RNA transcripts as drug targets
US8313908B2 (en) 2000-02-23 2012-11-20 The Trustees Of The University Of Pennsylvania Regulation of stem cell gene production with specific and selective electric and electromagnetic fields
US8791085B2 (en) 2009-05-28 2014-07-29 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
US8859515B2 (en) 2009-06-24 2014-10-14 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
US8895527B2 (en) 2009-05-22 2014-11-25 Curna, Inc. Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
US8912157B2 (en) 2010-01-06 2014-12-16 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
US8921329B2 (en) 2008-12-04 2014-12-30 Curna, Inc. Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO
US8921330B2 (en) 2009-06-26 2014-12-30 Curna, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
US8921334B2 (en) 2009-12-29 2014-12-30 Curna, Inc. Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
US8927511B2 (en) 2008-12-04 2015-01-06 Curna, Inc. Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
US8940708B2 (en) 2009-12-23 2015-01-27 Curna, Inc. Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
US8946182B2 (en) 2010-01-25 2015-02-03 Curna, Inc. Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
US8946181B2 (en) 2010-01-04 2015-02-03 Curna, Inc. Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
US8951981B2 (en) 2009-06-16 2015-02-10 Curna, Inc. Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
US8957037B2 (en) 2009-05-18 2015-02-17 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
US8962586B2 (en) 2010-02-22 2015-02-24 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
US8962585B2 (en) 2009-12-29 2015-02-24 Curna, Inc. Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
US8980857B2 (en) 2010-05-14 2015-03-17 Curna, Inc. Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4
US8980860B2 (en) 2010-07-14 2015-03-17 Curna, Inc. Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
US8980858B2 (en) 2010-05-26 2015-03-17 Curna, Inc. Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA
US8980856B2 (en) 2010-04-02 2015-03-17 Curna, Inc. Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
US8987225B2 (en) 2010-11-23 2015-03-24 Curna, Inc. Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
US8993533B2 (en) 2010-10-06 2015-03-31 Curna, Inc. Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
US9012139B2 (en) 2009-05-08 2015-04-21 Curna, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family
US9023822B2 (en) 2009-08-25 2015-05-05 Curna, Inc. Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
US9044494B2 (en) 2010-04-09 2015-06-02 Curna, Inc. Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
US9044493B2 (en) 2009-08-11 2015-06-02 Curna, Inc. Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin
US9068183B2 (en) 2009-12-23 2015-06-30 Curna, Inc. Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
US9074210B2 (en) 2009-02-12 2015-07-07 Curna, Inc. Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
US9089588B2 (en) 2010-05-03 2015-07-28 Curna, Inc. Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)
US9155754B2 (en) 2009-05-06 2015-10-13 Curna, Inc. Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1
US9163285B2 (en) 2009-05-06 2015-10-20 Curna, Inc. Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP
US9173895B2 (en) 2009-12-16 2015-11-03 Curna, Inc. Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
US9200277B2 (en) 2010-01-11 2015-12-01 Curna, Inc. Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
US9222088B2 (en) 2010-10-22 2015-12-29 Curna, Inc. Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
US9234199B2 (en) 2009-08-05 2016-01-12 Curna, Inc. Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS)
US9464287B2 (en) 2009-03-16 2016-10-11 Curna, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
US9593330B2 (en) 2011-06-09 2017-03-14 Curna, Inc. Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
US9677074B2 (en) 2009-12-31 2017-06-13 Curna, Inc. Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3)
US9708604B2 (en) 2009-03-17 2017-07-18 Curna, Inc. Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
US9725756B2 (en) 2009-08-21 2017-08-08 Curna, Inc. Treatment of ‘C terminus of HSP7O-interacting protein’ (CHIP) related diseases by inhibition of natural antisense transcript to CHIP
US9771579B2 (en) 2010-06-23 2017-09-26 Curna, Inc. Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
US10113166B2 (en) 2009-09-25 2018-10-30 Curna, Inc. Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity
US10214745B2 (en) 2012-03-15 2019-02-26 The Scripps Research Institute Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
US10358646B2 (en) 2008-12-04 2019-07-23 Curna, Inc. Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
US10370657B2 (en) 2009-06-16 2019-08-06 Curna, Inc. Treatment of Collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
US10563202B2 (en) 2009-07-24 2020-02-18 GuRNA, Inc. Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT)
US10583128B2 (en) 2011-09-06 2020-03-10 Curna, Inc. Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350428B2 (en) 2014-11-04 2019-07-16 Endonovo Therapetics, Inc. Method and apparatus for electromagnetic treatment of living systems
US8961385B2 (en) 2003-12-05 2015-02-24 Ivivi Health Sciences, Llc Devices and method for treatment of degenerative joint diseases with electromagnetic fields
US9656096B2 (en) 2003-12-05 2017-05-23 Rio Grande Neurosciences, Inc. Method and apparatus for electromagnetic enhancement of biochemical signaling pathways for therapeutics and prophylaxis in plants, animals and humans
US9415233B2 (en) 2003-12-05 2016-08-16 Rio Grande Neurosciences, Inc. Apparatus and method for electromagnetic treatment of neurological pain
US9440089B2 (en) 2003-12-05 2016-09-13 Rio Grande Neurosciences, Inc. Apparatus and method for electromagnetic treatment of neurological injury or condition caused by a stroke
US9433797B2 (en) 2003-12-05 2016-09-06 Rio Grande Neurosciences, Inc. Apparatus and method for electromagnetic treatment of neurodegenerative conditions
US8070703B2 (en) * 2004-03-10 2011-12-06 Vision Quest Industries Incorporated Electrically stimulating orthotic device and segmented liner
US8454543B2 (en) * 2004-03-10 2013-06-04 Vision Quest Industries Incorporated Electrodes for orthotic device
US8936560B2 (en) * 2004-03-10 2015-01-20 Vision Quest Industries Incorporated Bracing and electrostimulation for arthritis
KR20070024533A (en) 2004-04-19 2007-03-02 아이비비 테크놀로지스, 아이엔씨. Electromagnetic treatment apparatus and method
US7840272B2 (en) 2005-06-03 2010-11-23 Medrelief Inc. Methods for modulating osteochondral development using bioelectrical stimulation
US20080039901A1 (en) * 2005-06-03 2008-02-14 Kronberg James W Methods for modulating chondrocyte proliferation using pulsing electric fields
US8034014B2 (en) 2007-03-06 2011-10-11 Biomet Biologics, Llc Angiogenesis initation and growth
EP2620139B1 (en) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1 receptor antagonist rich solutions
US8612008B2 (en) * 2008-10-23 2013-12-17 Electromedical Products International, Inc. Microcurrent and cranial electrotherapy stimulator for control of anxiety, insomnia, depression and pain
IN2012DN04965A (en) 2009-11-25 2015-09-25 Difusion Technologies Inc
RU2526168C2 (en) 2009-12-11 2014-08-20 Дифьюжн Текнолоджиз, Инк. Method for making antimicrobial implants of polyetheretherketone
US9107765B2 (en) 2010-05-07 2015-08-18 Difusion Technologies, Inc. Medical implants with increased hydrophilicity
EP2611456A2 (en) 2010-09-03 2013-07-10 Biomet Biologics, LLC Methods and compositions for delivering interleukin-1 receptor antagonist
CA2813036A1 (en) 2010-10-01 2012-04-05 Ivivi Health Sciences, Llc Method and apparatus for electromagnetic treatment of head, cerebral and neural injury in animals and humans
EP2736588A4 (en) 2011-07-27 2015-06-10 Vision Quest Ind Inc Dba Vq Orthocare Electrostimulation system
US8343027B1 (en) 2012-01-30 2013-01-01 Ivivi Health Sciences, Llc Methods and devices for providing electromagnetic treatment in the presence of a metal-containing implant
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
EP3131628A4 (en) 2014-04-16 2017-11-22 Ivivi Health Sciences, LLC A two-part pulsed electromagnetic field applicator for application of therapeutic energy
WO2015187871A1 (en) * 2014-06-03 2015-12-10 Vomaris Innovations, Inc. Methods and devices for modulating gene expression and enzyme activity
US10806942B2 (en) 2016-11-10 2020-10-20 Qoravita LLC System and method for applying a low frequency magnetic field to biological tissues

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442846A (en) 1981-11-10 1984-04-17 University Of Pennsylvania Distributed port bone-piercing cathode for electrically stimulated osteogenesis
US4506674A (en) 1981-11-10 1985-03-26 Trustees Of The University Of Pennsylvania Method of stimulating osteogenesis with distributed port cathode
US4430999A (en) 1981-11-10 1984-02-14 Trustees Of The University Of Pennsylvania Osteogenesis stimulating cathode assembly for use with an internal fixation device
US4509520A (en) 1982-02-22 1985-04-09 Biolectron, Inc. Electrical stimulating apparatus
US4549547A (en) 1982-07-27 1985-10-29 Trustees Of The University Of Pennsylvania Implantable bone growth stimulator
US4467809A (en) 1982-09-17 1984-08-28 Biolectron, Inc. Method for non-invasive electrical stimulation of epiphyseal plate growth
US4467808A (en) * 1982-09-17 1984-08-28 Biolectron, Inc. Method for preventing and treating osteoporosis in a living body by using electrical stimulation non-invasively
US4487834A (en) 1982-09-17 1984-12-11 Biolectron, Inc. Electrical stimulation of articular chondrocytes
US5269746A (en) 1982-12-20 1993-12-14 Jacobson Jerry I Therapeutic treatment of mammals for epilepsy and Parkinson's disease
US4535775A (en) 1983-02-10 1985-08-20 Biolectron, Inc. Method for treatment of non-union bone fractures by non-invasive electrical stimulation
IT1159024B (en) 1983-06-02 1987-02-25 Ruggero Cadossi METHOD AND DEVICE FOR THE TREATMENT OF FABRICS AND LIVING CELLS THROUGH ELECTROMAGNETIC FIELDS BUTTONS
US4600010A (en) 1984-10-04 1986-07-15 Biolectron, Inc. Electric stimulator and test instrument therefor
US5014699A (en) * 1986-05-23 1991-05-14 Trustees Of The University Of Pennsylvania Electromagnetic method and apparatus for healing living tissue
US6120502A (en) 1988-06-13 2000-09-19 Michelson; Gary Karlin Apparatus and method for the delivery of electrical current for interbody spinal arthrodesis
US5038797A (en) 1990-02-20 1991-08-13 Romaine, Incorporated Electrical stimulation treatment device and method of use
US5273033A (en) 1991-09-19 1993-12-28 Murray Electronics Associates Limited Partnership Electrical stimulation for treatment of osteoarthritis
US5338286A (en) 1992-12-08 1994-08-16 Electro-Biology, Inc. Electromagnetic bioresponse by selective spectral suppression in pulsed field stimulation
US5374283A (en) 1993-12-01 1994-12-20 Flick; A. Bart Electrical therapeutic apparatus
US6261221B1 (en) 1996-11-01 2001-07-17 Amei Technologies Inc. Flexible coil pulsed electromagnetic field (PEMF) stimulation therapy system
US5743844A (en) 1996-11-01 1998-04-28 Amei Technologies, Inc. High efficiency pulsed electromagnetic field (PEMF) stimulation therapy method and system
US6132362A (en) 1996-11-01 2000-10-17 Amei Technologies, Inc. Pulsed electromagnetic field (PEMF) stimulation therapy system with bi-phasic coil
US5968527A (en) 1997-02-27 1999-10-19 Catholic University Of America, The Protection of living systems from the adverse effects of stress
US6083149A (en) 1997-10-22 2000-07-04 Emf Therapeutics, Inc. Magnetic field device and method for inhibiting angiogenesis and retarding growth rates of tumors in mammals
US6186940B1 (en) 1998-05-18 2001-02-13 Robert N. Kirschbaum Energized trace elements
RU2147895C1 (en) 1999-01-05 2000-04-27 Корж Геннадий Михайлович Method for treating uncomplicated fractures of the mandible
US6292699B1 (en) 1999-01-29 2001-09-18 Electro-Biology, Inc. Direct current stimulation of spinal interbody fixation device
JP2003525591A (en) 1999-04-29 2003-09-02 ノース・ショア・ロング・アイランド・ジューイッシュ・リサーチ・コーポレイション Methods for inducing neural tissue growth and enhancing survival
US6923784B2 (en) 1999-04-30 2005-08-02 Medtronic, Inc. Therapeutic treatment of disorders based on timing information
DE19933719A1 (en) 1999-07-19 2001-01-25 Medigene Ag Structural protein in adeno-associated virus with altered chromatographic properties, its production and use
US7374916B2 (en) * 2000-02-23 2008-05-20 The Trustees Of The University Of Pennsylvania Regulation of aggrecan gene expression using specific and selective electrical and electromagnetic signals
US7022506B2 (en) 2000-02-23 2006-04-04 The Trustees Of The University Of Pennsylvania Method and device for treating osteoarthritis, cartilage disease, defects and injuries in the human knee
US7465546B2 (en) * 2000-02-23 2008-12-16 The Trustees Of The University Of Pennsylvania Regulation of transforming growth factor-beta (TGF-β) gene expression in living cells via the application of specific and selective electric and electromagnetic fields
US7130692B2 (en) * 2000-02-23 2006-10-31 The Trustees Of The University Of Pennsylvania Portable electrotherapy device for treating osteoarthritis and other diseases, defects and injuries of the knee joint
US7465566B2 (en) * 2000-02-23 2008-12-16 The Trustees Of The University Of Pennsylvania Regulation of genes via application of specific and selective electrical and electromagnetic signals
WO2005070136A2 (en) 2004-01-12 2005-08-04 The Trustees Of The University Of Pennsylvania Up-regulation of bone morphogenetic protein (bmp) gene expression in bone cells by electromagnetic signals
US7429471B2 (en) 2000-02-23 2008-09-30 The Trustees Of The University Of Pennsylvania Regulation of matrix metalloproteinase gene expression using specific and selective electrical and electromagnetic signals
US6485963B1 (en) 2000-06-02 2002-11-26 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Growth stimulation of biological cells and tissue by electromagnetic fields and uses thereof
AU2002227147A1 (en) 2000-11-02 2002-05-15 Keith L March Method and system for modulation of oscillating signals to enhance biologic effects
US20050049640A1 (en) 2003-05-12 2005-03-03 Gurtner Geoffrey C. Electromagnetic fields increase in vitro and in vivo angiogenesis through endothelial release of FGF-2
WO2005049132A1 (en) * 2003-11-14 2005-06-02 The Trustees Of The University Of Pennsylvania Method and device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1716228A4 *

Cited By (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981611B2 (en) 2000-02-23 2011-07-19 The Trustees Of The University Of Pennsylvania Regulation of fibroblastic growth factor-2 (FGF-2) gene expression in living cells with the application of specific and selective electric and electromagnetic fields
US8017369B2 (en) 2000-02-23 2011-09-13 The Trustees Of The University Of Pennsylvania System and method of up-regulating bone morphogenetic proteins (BMP) gene expression in bone cells via the application of fields generated by specific and selective electric and electromagnetic signals
US7468264B2 (en) 2000-02-23 2008-12-23 The Trustees Of The University Of Pennsylvania Method and device for treating osteoarthritis, cartilage disease, defects and injuries in the human knee
US7465546B2 (en) 2000-02-23 2008-12-16 The Trustees Of The University Of Pennsylvania Regulation of transforming growth factor-beta (TGF-β) gene expression in living cells via the application of specific and selective electric and electromagnetic fields
US7022506B2 (en) 2000-02-23 2006-04-04 The Trustees Of The University Of Pennsylvania Method and device for treating osteoarthritis, cartilage disease, defects and injuries in the human knee
US7374916B2 (en) 2000-02-23 2008-05-20 The Trustees Of The University Of Pennsylvania Regulation of aggrecan gene expression using specific and selective electrical and electromagnetic signals
US7429471B2 (en) 2000-02-23 2008-09-30 The Trustees Of The University Of Pennsylvania Regulation of matrix metalloproteinase gene expression using specific and selective electrical and electromagnetic signals
US7465566B2 (en) 2000-02-23 2008-12-16 The Trustees Of The University Of Pennsylvania Regulation of genes via application of specific and selective electrical and electromagnetic signals
US8313908B2 (en) 2000-02-23 2012-11-20 The Trustees Of The University Of Pennsylvania Regulation of stem cell gene production with specific and selective electric and electromagnetic fields
US8065015B2 (en) 2000-02-23 2011-11-22 The Trustees Of The University Of Pennsylvania Regulation of genes via application of specific and selective electrical and electromagnetic signals
US7130692B2 (en) 2000-02-23 2006-10-31 The Trustees Of The University Of Pennsylvania Portable electrotherapy device for treating osteoarthritis and other diseases, defects and injuries of the knee joint
USRE41391E1 (en) 2000-02-23 2010-06-22 The Trustees Of The University Of Pennsylvania Regulation of type II collagen gene expression using specific and selective electrical and electromagnetic signals
US7167753B2 (en) 2001-07-03 2007-01-23 The Trustees Of The University Of Pennsylvania Device and method for electrically inducing osteogenesis in the spine
US7158835B2 (en) 2001-12-21 2007-01-02 The Trustees Of The University Of Pennsylvania Device for treating osteoporosis, hip and spine fractures and fusions with electric fields
US7215995B2 (en) 2003-11-14 2007-05-08 The Trustees Of The University Of Pennsylvania Method and device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip
US9803195B2 (en) 2005-12-28 2017-10-31 The Scripps Research Institute Natural antisense and non-coding RNA transcripts as drug targets
US8288354B2 (en) 2005-12-28 2012-10-16 The Scripps Research Institute Natural antisense and non-coding RNA transcripts as drug targets
US10472627B2 (en) 2005-12-28 2019-11-12 The Scripps Research Institute Natural antisense and non-coding RNA transcripts as drug targets
JP2009538694A (en) * 2006-05-31 2009-11-12 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア Regulation of transforming growth factor-beta (TGF-β) gene expression in living cells through the application of specific and selective electric and electromagnetic fields
US8153606B2 (en) 2008-10-03 2012-04-10 Opko Curna, Llc Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
US9765336B2 (en) 2008-12-04 2017-09-19 Curna, Inc. Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO
US10358646B2 (en) 2008-12-04 2019-07-23 Curna, Inc. Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
US9410155B2 (en) 2008-12-04 2016-08-09 Curna, Inc. Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
US8921329B2 (en) 2008-12-04 2014-12-30 Curna, Inc. Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO
US11697814B2 (en) 2008-12-04 2023-07-11 Curna, Inc. Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
US8927511B2 (en) 2008-12-04 2015-01-06 Curna, Inc. Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
US10358645B2 (en) 2008-12-04 2019-07-23 Curna, Inc. Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO
US10519448B2 (en) 2009-02-12 2019-12-31 Curna, Inc. Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
US9074210B2 (en) 2009-02-12 2015-07-07 Curna, Inc. Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
US10995334B2 (en) 2009-03-16 2021-05-04 Curna Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
US9464287B2 (en) 2009-03-16 2016-10-11 Curna, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
US9834769B2 (en) 2009-03-17 2017-12-05 Curna, Inc. Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
US9708604B2 (en) 2009-03-17 2017-07-18 Curna, Inc. Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
US9163285B2 (en) 2009-05-06 2015-10-20 Curna, Inc. Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP
US10604755B2 (en) 2009-05-06 2020-03-31 Curna, Inc. Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
US9957503B2 (en) 2009-05-06 2018-05-01 Curna, Inc. Treatment of LCAT gene related diseases by inhibition of a natural antisense transcript to LCAT
US9155754B2 (en) 2009-05-06 2015-10-13 Curna, Inc. Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1
US9611477B2 (en) 2009-05-06 2017-04-04 Curna, Inc. Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP
US9012139B2 (en) 2009-05-08 2015-04-21 Curna, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family
US9533004B2 (en) 2009-05-08 2017-01-03 Curna, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family
US9914923B2 (en) 2009-05-18 2018-03-13 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
US8957037B2 (en) 2009-05-18 2015-02-17 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
US10487327B2 (en) 2009-05-18 2019-11-26 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
US9725717B2 (en) 2009-05-22 2017-08-08 Curna, Inc. Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to TFE3
US8895527B2 (en) 2009-05-22 2014-11-25 Curna, Inc. Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3
US9512427B2 (en) 2009-05-28 2016-12-06 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
US8791085B2 (en) 2009-05-28 2014-07-29 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
US9133456B2 (en) 2009-05-28 2015-09-15 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
US8951981B2 (en) 2009-06-16 2015-02-10 Curna, Inc. Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
US11339394B2 (en) 2009-06-16 2022-05-24 Curna, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
US9714423B2 (en) 2009-06-16 2017-07-25 Curna, Inc. Treatment of Paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
US10370657B2 (en) 2009-06-16 2019-08-06 Curna, Inc. Treatment of Collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
US8859515B2 (en) 2009-06-24 2014-10-14 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
US9771593B2 (en) 2009-06-24 2017-09-26 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
US10876117B2 (en) 2009-06-26 2020-12-29 Curna, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
US10450567B2 (en) 2009-06-26 2019-10-22 Curna, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
US8921330B2 (en) 2009-06-26 2014-12-30 Curna, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
US10036014B2 (en) 2009-06-26 2018-07-31 Curna, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
US10563202B2 (en) 2009-07-24 2020-02-18 GuRNA, Inc. Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT)
US9234199B2 (en) 2009-08-05 2016-01-12 Curna, Inc. Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS)
US9044493B2 (en) 2009-08-11 2015-06-02 Curna, Inc. Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin
US9909126B2 (en) 2009-08-11 2018-03-06 Curna, Inc. Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ)
US9290766B2 (en) 2009-08-11 2016-03-22 Curna, Inc. Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)
US10316317B2 (en) 2009-08-11 2019-06-11 Curna, Inc. Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)
US9725756B2 (en) 2009-08-21 2017-08-08 Curna, Inc. Treatment of ‘C terminus of HSP7O-interacting protein’ (CHIP) related diseases by inhibition of natural antisense transcript to CHIP
US9528110B2 (en) 2009-08-25 2016-12-27 Curna, Inc. Treatment of ‘IQ motif containing gtpase activating protein’ (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
US9023822B2 (en) 2009-08-25 2015-05-05 Curna, Inc. Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
US10113166B2 (en) 2009-09-25 2018-10-30 Curna, Inc. Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity
US11390868B2 (en) 2009-09-25 2022-07-19 Curna, Inc. Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity
US9173895B2 (en) 2009-12-16 2015-11-03 Curna, Inc. Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
US9879264B2 (en) 2009-12-16 2018-01-30 Curna, Inc. Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
US10221413B2 (en) 2009-12-23 2019-03-05 Curna, Inc. Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
US8940708B2 (en) 2009-12-23 2015-01-27 Curna, Inc. Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
US9879256B2 (en) 2009-12-23 2018-01-30 Curna, Inc. Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
US9068183B2 (en) 2009-12-23 2015-06-30 Curna, Inc. Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
US9663785B2 (en) 2009-12-29 2017-05-30 Curna, Inc. Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
US8962585B2 (en) 2009-12-29 2015-02-24 Curna, Inc. Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
US9732339B2 (en) 2009-12-29 2017-08-15 Curna, Inc. Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
US8921334B2 (en) 2009-12-29 2014-12-30 Curna, Inc. Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
US9677074B2 (en) 2009-12-31 2017-06-13 Curna, Inc. Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3)
US9834767B2 (en) 2010-01-04 2017-12-05 Curna, Inc. Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
US8946181B2 (en) 2010-01-04 2015-02-03 Curna, Inc. Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
US9267136B2 (en) 2010-01-06 2016-02-23 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
US8912157B2 (en) 2010-01-06 2014-12-16 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
US9200277B2 (en) 2010-01-11 2015-12-01 Curna, Inc. Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
US10696966B2 (en) 2010-01-11 2020-06-30 Curna, Inc. Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
US9745582B2 (en) 2010-01-25 2017-08-29 Curna, Inc. Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
US8946182B2 (en) 2010-01-25 2015-02-03 Curna, Inc. Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
US10337013B2 (en) 2010-01-25 2019-07-02 Curna, Inc. Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
US9382543B2 (en) 2010-02-22 2016-07-05 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
US9902995B2 (en) 2010-02-22 2018-02-27 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related disease by inhibition of natural antisense transcript to PYCR1
US8962586B2 (en) 2010-02-22 2015-02-24 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
US8980856B2 (en) 2010-04-02 2015-03-17 Curna, Inc. Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
US9920369B2 (en) 2010-04-02 2018-03-20 Curna, Inc. Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisene transcript to CSF3
US9382538B2 (en) 2010-04-02 2016-07-05 Curna, Inc. Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
US9044494B2 (en) 2010-04-09 2015-06-02 Curna, Inc. Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
US9745580B2 (en) 2010-04-09 2017-08-29 Curna, Inc. Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
US10337011B2 (en) 2010-04-09 2019-07-02 Curna, Inc. Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
US9089588B2 (en) 2010-05-03 2015-07-28 Curna, Inc. Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)
US11408004B2 (en) 2010-05-03 2022-08-09 Curna, Inc. Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT)
US10100315B2 (en) 2010-05-14 2018-10-16 Curna, Inc. Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4
US8980857B2 (en) 2010-05-14 2015-03-17 Curna, Inc. Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4
US9745584B2 (en) 2010-05-14 2017-08-29 Curna, Inc. Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4
US9624493B2 (en) 2010-05-26 2017-04-18 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
US8980858B2 (en) 2010-05-26 2015-03-17 Curna, Inc. Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA
US9970008B2 (en) 2010-05-26 2018-05-15 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
US10174324B2 (en) 2010-05-26 2019-01-08 Curna, Inc. Treatment of Methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA
US10253320B2 (en) 2010-05-26 2019-04-09 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
US9771579B2 (en) 2010-06-23 2017-09-26 Curna, Inc. Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA
US10793857B2 (en) 2010-06-23 2020-10-06 Curna, Inc. Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA
US9902958B2 (en) 2010-07-14 2018-02-27 Curna, Inc. Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
US9394542B2 (en) 2010-07-14 2016-07-19 Curna, Inc. Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
US8980860B2 (en) 2010-07-14 2015-03-17 Curna, Inc. Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
US8993533B2 (en) 2010-10-06 2015-03-31 Curna, Inc. Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
US9873873B2 (en) 2010-10-22 2018-01-23 Curna, Inc. Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
US9222088B2 (en) 2010-10-22 2015-12-29 Curna, Inc. Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
US9809816B2 (en) 2010-11-23 2017-11-07 Curna, Inc. Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
US8987225B2 (en) 2010-11-23 2015-03-24 Curna, Inc. Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
US9902959B2 (en) 2011-06-09 2018-02-27 Curna, Inc. Treatment of Frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
US9593330B2 (en) 2011-06-09 2017-03-14 Curna, Inc. Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
US10583128B2 (en) 2011-09-06 2020-03-10 Curna, Inc. Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules
US10214745B2 (en) 2012-03-15 2019-02-26 The Scripps Research Institute Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF

Also Published As

Publication number Publication date
NO20063444L (en) 2006-10-10
IL176783A (en) 2014-05-28
EP1716228A2 (en) 2006-11-02
CA2553199C (en) 2014-03-25
RU2388817C2 (en) 2010-05-10
ZA200605716B (en) 2008-11-26
WO2005070136A3 (en) 2005-10-06
CN1918285B (en) 2013-09-25
CN1918285A (en) 2007-02-21
JP4801802B2 (en) 2011-10-26
US20070299472A1 (en) 2007-12-27
KR20060129256A (en) 2006-12-15
KR101324824B1 (en) 2013-11-01
BRPI0506826A (en) 2007-05-29
IL176783A0 (en) 2006-10-31
CA2553199A1 (en) 2005-08-04
AU2005206794A1 (en) 2005-08-04
AU2005206794B2 (en) 2010-09-16
EP1716228A4 (en) 2009-06-17
NZ548447A (en) 2010-04-30
JP2007517624A (en) 2007-07-05
US8017369B2 (en) 2011-09-13
RU2006129306A (en) 2008-02-20

Similar Documents

Publication Publication Date Title
US8017369B2 (en) System and method of up-regulating bone morphogenetic proteins (BMP) gene expression in bone cells via the application of fields generated by specific and selective electric and electromagnetic signals
US7465546B2 (en) Regulation of transforming growth factor-beta (TGF-β) gene expression in living cells via the application of specific and selective electric and electromagnetic fields
EP1575475B1 (en) Regulation of type ii collagen gene expression using specific and selective electrical and electromagnetic signals
CA2529374C (en) Regulation of matrix metalloproteinase gene expression using specific and selective electrical and electromagnetic signals
CA2500212A1 (en) Resolution of aggrecan gene expression using specific and selective electrical and electromagnetic signals
US8313908B2 (en) Regulation of stem cell gene production with specific and selective electric and electromagnetic fields
AU2009212561B2 (en) Regulation of Fibroblastic Growth Factor-2 (FGF-2) gene expression in living cells with the application of specific and selective electric an electromagnetic fields
WO2008017023A2 (en) Regulation of vascular endothelial growth factor (vegf) gene expression in tissue via the application of electric and/or electromagnetic fields
MXPA06007918A (en) Up-regulation of bone morphogenetic protein (bmp) gene expression in bone cells by electromagnetic signals

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/007918

Country of ref document: MX

Ref document number: 2553199

Country of ref document: CA

Ref document number: 200605716

Country of ref document: ZA

Ref document number: 12006501331

Country of ref document: PH

Ref document number: 548447

Country of ref document: NZ

Ref document number: 176783

Country of ref document: IL

Ref document number: 1946/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005206794

Country of ref document: AU

Ref document number: 1020067013999

Country of ref document: KR

Ref document number: 2006549515

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2005206794

Country of ref document: AU

Date of ref document: 20050111

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005206794

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2005705445

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005705445

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580004711.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2006129306

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005705445

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067013999

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10585718

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0506826

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10585718

Country of ref document: US